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Purpose: Dose information from organ sub-regions has been shown to be more
predictive of genitourinary toxicity than whole organ dose volume histogram information.
This study aimed to identify anatomically-localized regions where 3D dose is associated
with genitourinary toxicities in healthy tissues throughout the pelvic anatomy.
Methods and Materials: Dose distributions for up to 656 patients of the Trans-Tasman
Radiation Oncology Group 03.04 RADAR trial were deformably registered onto a single
exemplar CT dataset. Voxel- based multiple comparison permutation dose difference
testing, Cox regression modeling and LASSO feature selection were used to identify
regions where 3D dose-increase was associated with late grade ≥ 2 genitourinary
dysuria, incontinence and frequency, and late grade ≥ 1 haematuria. This was externally
validated by registering dose distributions from the RT01 (up to n = 388) and CHHiP (up
to n = 247) trials onto the same exemplar and repeating the voxel-based tests on each
of these data sets. All three datasets were then combined, and the tests repeated.
Results: Voxel-based Cox regression and multiple comparison permutation dose
difference testing revealed regions where increased dose was correlated with
genitourinary toxicity. Increased dose in the vicinity of the membranous and spongy
Marcello et al. Voxel-Based Dose-Toxicity Modeling
urethra was associated with dysuria for all datasets. Haematuria was similarly correlated
with increased dose at the membranous and spongy urethra, for the RADAR, CHHiP, and
combined datasets. Some evidence was found for the association between incontinence
and increased dose at the internal and external urethral sphincter for RADAR and
the internal sphincter alone for the combined dataset. Incontinence was also strongly
correlated with dose from posterior oblique beams. Patients with fields extending
inferiorly and posteriorly to the CTV, adjacent to the membranous and spongy urethra,
were found to experience increased frequency.
Conclusions: Anatomically-localized dose-toxicity relationships were determined for
late genitourinary symptoms in the urethra and urinary sphincters. Low-intermediate
doses to the extraprostatic urethra were associated with risk of late dysuria and
haematuria, while dose to the urinary sphincters was associated with incontinence.
Keywords: external beam radiotherapy, prostate cancer, urinary toxicity, voxel-based analysis, dose-toxicity
relationships
INTRODUCTION
External beam radiotherapy (EBRT) is a prominent treatment
option for prostate cancer patients (1), resulting in genitourinary
(GU) toxicity with an even higher incidence than rectal
toxicity (2). Relationships between treatment and patient specific
risk factors, and GU toxicity have been established (3–5).
More evidence of GU dose-toxicity relationships is required
as more conformal techniques (6, 7) have introduced dose-
escalated treatments.
Risk estimation used in establishing dose constraints for
healthy organs at risk (OARs) associated with GU toxicity, such
as the bladder and urethra, is typically based on considering
the planned dose to the whole organ according to dose volume
histogram (DVH) or dose surface histogram (DSH) information.
This is problematic, however, as it ignores potential spatially
varied intra-organ radio-sensitivity. Intuitively, planned dose
to symptom related sub-regions (SRSs) of the urethra and
bladder has been shown to be more predictive of GU symptoms
than information derived from whole-organ DVHs (8). Further
understanding of the relationship between dose and urinary
toxicity at the voxel level could assist in identifying new SRSs,
confirm established SRSs, and help provide these SRS with
optimal dose constraints. This would restrict dose to healthy
tissues with more spatial specificity, and thus help reduce GU
toxicity in patients while maintaining tumor control.
Evidence is accumulating for the establishment of
relationships between acute and late GU toxicity and spatial dose
variance, particularly within the prostatic urethra (8), at various
regions on the surface of the bladder (9, 10), the bladder trigone
(11–13), the bladder neck (14) and at subregions within the
bladder volume (8). No study to date, however, has performed
a voxel-based analysis searching for correlation between dose
variation and GU toxicity throughout the entire pelvic anatomy
without the assumption that dose-toxicity relationships are
limited to within OAR volumes or surfaces. This would enable
the identification of dose-toxicity relationships in a broader
range of the urinary tract, beyond the prostatic urethra to the
membranous and spongy urethra. This extended naïve analysis
may also improve understanding of how broader dose patterns,
such as those representative of treatment technique (e.g., beam
arrangement), relate to toxicity.
In this study, multiple voxel-based statistical methods were
employed to investigate the association between 3D planned dose
and measures of late GU toxicity in the entire pelvic anatomy.
Many shortcomings have typically hindered previous voxel-based
analyses (15, 16), including misregistration of planned 3D dose
distributions, false positive rates due to the large number of
voxels being statistically compared, not using time-to-event data,
or not controlling for patient baseline characteristics. This study
performed a combination of statistical tests to compensate for
these shortcomings. High quality planned dose data from three
prospective multi-center prostate radiotherapy clinical trials was
utilized in order to assess the consistency of derived associations
across cohorts, participating centers, employed radiotherapy
techniques and overall treatment approach. “Validation” was
defined as applying the same voxel-based tests to datasets from
two other trials, with one trial providing a cohort similar
to that of the primary dataset and the other substantially
different (primarily in terms of treatment technique). This
validation determined whether the emergent dose-toxicity
patterns within the primary dataset were generalizable to these
(similar and different) external datasets. This validation also had
an exploratory element, in that it enabled the identification of
new emergent patterns in the external datasets regardless of
whether they matched the patterns in the primary datasets.
METHODS AND MATERIALS
RADAR Trial
Coordinated by the Trans-Tasman Radiation Oncology
Group (TROG), the Randomized Androgen Deprivation and
Radiotherapy (RADAR) phase 3 factorial trial (TROG 03.04)
compared 6 months of androgen deprivation therapy (ADT)
plus radiotherapy with 18 months of ADT with the same
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radiotherapy, with and without bisphosphonates (17, 18).
Accruing a total of 1071 men between October 2003 and August
2007, trial patients had T2 – T4 prostate cancer, undergoing
dose-escalated 3D conformal EBRT with prescribed doses of 66,
70 or 74Gy, or 46Gy EBRT combined with a brachytherapy
boost. Plans could be generated with any preferred combination
of 3 or more conformal beams. 3D planned dose distributions
with corresponding CT images including delineated CTV,
rectum and bladder were collected and utilized as the primary
dataset for this study. RADAR was the first TROG trial to
incorporate full electronic review of the treatment planning
data of accrued patients, facilitated by use of the SWAN system
(19). See Table 1 for information on each trial summarized for
direct comparison.
RT01 Trial
The RT01 phase 3, international, superiority, randomized
controlled trial compared dose-escalated conformal radiotherapy
with standard-dose conformal radiotherapy (20, 21). Accruing
a total of 843 men between January 1998 and December 2001,
patients had confirmed T1b – T3a prostate cancer. The patients
underwent 3D conformal EBRT with either a conventional
prescribed dose of 64Gy using prescribed arrangements of either
3 or 4 beams, or the same with an additional 4 or 6 beam boost to
74Gy. ADTwas recommended for 6months. Similar 3D planned
dose distributions, CT and delineation data were collected and
utilized as the first external validation dataset of this study. The
trial was managed by the Medical Research Council Clinical
Trials Unit at University College, London.
CHHiP Trial
The CHHiP randomized phase 3 non-inferiority trial compared
conventional and hypofractionated prostate Intensity Modulated
Radiotherapy (IMRT) (22, 23). 3,216 men with T1b–T3a
localized prostate cancer were accrued to the trial between
October 2002 and June 2011. These underwent IMRT with
a conventional prescribed dose of 74Gy in 2Gy fractions or
hypofractionated courses of 60Gy or 57Gy in 3Gy fractions,
all with optional IGRT. ADT was recommended for 6 months,
but was optional for patients with low risk disease. Similar 3D
planned data was utilized as the second external validation data
set for this study. Data was limited to an early cohort of CHHiP
patients with processed DICOM information available at the time
of acquisition. This trial was managed by the Clinical Trials and
Statistics Unit at The Institute of Cancer Research, UK.
3D Data Preparation
Three CT image templates were chosen from an independent
cohort of 39 prostate EBRT patients (26). Pairwise registrations
of CT images within this cohort along with registrations between
this cohort and the RADAR CT dataset were used to generate a
normalized cross correlation similarity matrix. This matrix was
used to perform clustering by affinity propagation to select the
single most representative patient CT as an exemplar from the
initial cohort. This exemplar was the first registration template
(T1). Next, an anti-exemplar, most-different from T1, was chosen
as a template on which the impact of registration and reference
geometry could be tested (T2). Finally, a similar process was
used to select a cropped exemplar, enabling analysis to be
restricted to a small region including the prostate and immediate
surrounding organs (T3). Dose distributions were then deformed
onto these templates through application of deformation vector
fields obtained from the image-based registrations above. All
registration and dose deformation were performed in 3D. See
Appendix Section 2 for images of templates and registration
pipelines. The 3D dose distributions from all phases of
radiotherapy were summed together according to biologically
isoeffective 2Gy per fraction dose (EQD2) (27), using a spatially
invariant alpha/beta ratio of 3, resulting in a single distribution
for each patient registered onto each template. The number of
voxels and dimensions of the CT image of each registration
template and corresponding dose distributions are as follows:
T1: 332× 249× 64 voxels
voxel size: 1.17× 1.17× 2 mm
T2: 327× 178× 76 voxels
voxel size: 1.17× 1.17× 2.5 mm
T3: 132× 130× 129 voxels
voxel size: 1.24× 1.24× 1 mm
Dose distributions used in this analysis were uniformly sampled 1
in 2 voxels for T1 and T2 (due to the large number of total voxels).
For T3, every voxel was used.
Genitourinary Toxicity Endpoints
Four time-to-event GU toxicity endpoints were included
for analysis: urinary dysuria, haematuria, incontinence and
frequency. For each endpoint, an event consisted of the first
peak grade ≥ 2 occurrence during follow-up. For haematuria,
however, grade ≥ 1 events were considered instead, due to the
rarity of grade ≥ 2 events in the RADAR cohort. All toxicity
events were late (> 3 months). All patients who experienced
baseline toxicity of grade ≥ 1 were removed from analysis,
apart from potential baseline dysuria and haematuria patients
from the RT01 dataset, as this information was not available.
Physician assisted toxicity grading was performed according
to the Late Effects on Normal Tissue, Subjective, Objective,
Management, Analytic (LENT/SOMA) questionnaire (28). For
RADAR, patients were routinely followed up, post-treatment,
approximately every 3 months for 18 months, every 6 months
to 5 years, and annually thereafter. RT01 patients were assessed
for toxicities at 6, 12, 18, and 24 months after commencing
radiotherapy, and annually thereafter. CHHiP patients were
assessed for late side-effects beginning 26 weeks after the start
of radiotherapy and every 6 months for 2 years, and then
annually thereafter.
Note that all voxel-based tests were repeated for all four
endpoints, on all three trial datasets (RADAR, RT01 and CHHiP),
as well as on a dataset combining patients from all trials
(“Combined”). All three registration templates were used for
RADAR for exploration of dose-toxicity associations, but only T1
for RT01, CHHiP and Combined for validation. The permutation
and uni-voxel tests were performed using MATLAB R2016b
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TABLE 1 | Clinical trials information.
RADAR RT01 CHHiP
Full name Randomized Androgen Deprivation and
Radiotherapy (TROG 03.04) Trial (17, 18)
A Randomized Trial of High Dose Therapy
in Localized Cancer of the Prostate using
Conformal Radiotherapy Techniques
(20, 21)
Conventional or Hypofractionated High Dose
Intensity Modulated Radiotherapy for Prostate
Cancer Trial (22, 23)
Descriptors • Randomized
• Phase 3
• Factorial
• Randomized
• Phase 3
• Superiority
• Randomized
• Phase 3
• Non-inferiority
Goal Comparison of 6 months of androgen
deprivation therapy (ADT) plus radiotherapy
with 18 months of ADT with the same
radiotherapy
Comparison of 64Gy standard-dose and
74Gy dose-escalated conformal
radiotherapy
Comparison of conventional and
hypofractionated IMRT
Countries Australia and New Zealand United Kingdom, New Zealand, Australia United Kingdom, New Zealand, Rep. of Ireland,
Switzerland
Accrual years Oct 2003 – Aug 2007 Jan 1998 – Dec 2001 Oct 2002 – Jun 2011
Total accrued patients 1071 843 3216
Date data was frozen June 2015 Aug 2013 Oct 2017
Patients Intermediate-risk (T2a) or high-risk (T2b+)
prostate cancer
T1b – T3a prostate cancer T1b – T3a prostate cancer
Radiotherapy type Dose escalated 3D conformal EBRT Standard or dose escalated 3D conformal
EBRT
Dose escalated IMRT
Prescribed dose groups
(dose per fraction)
66Gy (2Gy), 70Gy (2Gy), 74Gy (2Gy) 64Gy (2Gy), 74Gy (2Gy) 57Gy (3Gy), 60Gy (3Gy), 74Gy (2Gy)
Beam arrangements Any preferred combination of 3 or more
conformal beams
3 or 4 beams (anterior/lateral/posterior) for
first 64Gy, with additional 4 or 6 beam
boost to 74Gy
3 or 4 beams (anterior/lateral/posterior) or 5
beams or more if inverse planning utilized
Electronic review of
treatment planning data
Full retrospectve review for all patients (19) No electronic individual plan review (24) Full prospective case reviews for the first 2 or 3
patients at each center (25)
Manager TROG Cancer Research, NSW, Australia Medical Research Clinical Trials Unit,
London, UK
Clinical Trials and Statistics Unit, the Institute of
Cancer Research, London, UK
Trial registration number ISRCTN90298520 ISRCTN47772397 ISRCTN97182923
Ethics approval number Approved by Hunter New England Human
Research Ethics Committee Trial ID
03/06/11/3.02
North Thames Multi-center Research
Ethics Committee number MREC/97/2/16
Approved by the London Multi-center Research
Ethics Committee number 04/MRE02/10
and later versions (MathWorks, Natick MA), while the multi-
voxel LASSO test was performed on R 3.6.1 (The R Foundation,
Vienna). All 3D results were displayed using ITK-SNAP version
3.8.0 (29).
Voxel-Based Dose Difference
Permutation Test
It is recommended that Figure 1 is closely followed while reading
through the following descriptions of the voxel-based tests.
This test was performed according to the method outlined
by Chen et al. (16). Following (Figure 1A), for each given
toxicity endpoint, patients were divided according to whether
they experienced a toxicity event at any time during follow-
up. The mean dose distributions of each group were then
compared to each other, voxel-by-voxel, to reveal regions of
statistically significant dose difference. This method utilizes
a non-parametric permutation-based test in which the group
labels (for the with and without toxicity groups) are randomly
swapped (permuted) and the dose-comparison repeated for each
permutation. 1,000 permutations were performed generating a
distribution of test statistics. Each test statistic was calculated as
the maximum value across all voxels of the locally normalized
dose difference in each voxel for both the true labeling sample
and all random permuted samples. The null hypothesis was that
the mean of the distribution of dose values in a given voxel for the
with toxicity group is not different to the without toxicity group.
To find voxels of significant dose-difference between the with and
without toxicity groups at any given p-value α, a test statistic
T was calculated as the (1 – α) percentile of the test statistics
distribution from the random permuted samples. Voxels where
the locally normalized dose difference values for the true labeling
sample were greater than T are voxels where the dose difference
between the with and without toxicity groups is statistically
significant at the p = α level. In this study, thresholds of p <
0.05, p < 0.1, p < 0.2, and p < 0.3 were applied. Multiple p-value
thresholds were applied in an attempt to thoroughly explore the
dose difference, accounting for the conservative nature of the
permutation test (see section discussion for further explanation).
This test accounts for the multiple statistical testing problem
arising from comparing a vast number of voxels (seeAppendix A
of Chen et al. for more detail). As shown in Figure 1, the mean
dose difference map was imposed on the registration template,
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FIGURE 1 | Visual representation of the (A) Voxel-Based Dose Difference Permutation Test, (B) Uni-Voxel Cox Regression test and (C) Multi-Voxel Cox Regression
Test with LASSO Feature Selection.
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including the delineated CTV, bladder and rectum. If the dose
difference reached statistical significance at one of the given p-
value thresholds, then the voxels corresponding to this difference
(the thresholded p-value map) were highlighted in green and
imposed onto the dose difference map.
Uni-Voxel Cox Regression Test
This test generates a separate Cox proportional hazards model
for each voxel (hence, “uni”-voxel), testing for association
between dose in that voxel and incidence of the toxicity
endpoint. Taking a given voxel, patients were divided into
two groups about the median of the combined distribution
of dose values, as in Figure 1B). The hazard ratio (HR) of
the incidence of the endpoint between the high dose value
group and low dose value group was then calculated, including
a corresponding p-value determining whether the HR was
significantly greater than or <1 at the p < 0.05 level. This
HR therefore compares the incidence of toxicity between each
dose group, indicating the dose-toxicity relationship at the given
voxel. Age, prescribed dose, disease risk, cancer stage, baseline
PSA concentration and number of treatment beams were patient
baseline characteristics investigated as potential control variables
in each model, attempting to eliminate their confounding
influence at each voxel (30, 31). These were chosen through
an automated selection procedure (see Appendix Section 1 for
details). Repeating this entire process for every voxel produced
a 3D HR map and corresponding p-value map revealing the
relationship between dose and the given toxicity endpoint across
the pelvic anatomy. The continuous HR map was first imposed
on the anatomical template. Following this, the thresholded
p-value map was imposed onto the HR map, showing (in
green) voxels where HR < 1 or HR > 1 at the p <
0.05 level.
Multi-Voxel Cox Regression Test With
LASSO Feature Selection
This test is represented in Figure 1C). In contrast to the uni-
voxel Cox regression test, this test combined all voxel-dose
variables across the pelvic anatomy into a single multivariate
Cox regression model (hence, “multi”-voxel). The LASSO [Least
Absolute Shrinkage Selection Operator (32)] was then applied to
select voxels (voxel-dose variables) that did not correlate with
each other in the model, while still correlating strongly with the
toxicity endpoint. The LASSO requires a pre-specified variable,
λ, that determines the threshold by which features or variables
(voxels) in the Cox model are selected. As λ increases, more
features are excluded, until none are selected. 100 values of λ
were pre-specified, equally spaced from that which selected all
voxels to that which selected none. For each value of λ, one-in-
ten cross validation was used to test the predictive ability of the
resulting Coxmodel – the model comprised of the voxels selected
by the LASSO. The final value of λ was that which maximized
the given model’s ability to predict the toxicity endpoint hazard
rate by minimizing the partial likelihood deviance. The selected
voxels were then imposed on the anatomical template, indicating
whether HR > 1 or HR < 1 in each case. As with the
univoxel Cox regression test, HRs in this test compared the
incidence of the endpoint (e.g., dysuria) between the high dose
group and low dose group at a given voxel, with the cut-point
for dose determined in the same way. The LASSO enabled
selection of voxels strongly correlated with the endpoint while
accounting for inter-voxel dose correlation and the multiple
testing problem.
RESULTS
Trial Datasets
Tables 2, 3 show the number of patients from each trial included
for each endpoint’s respective analysis, with corresponding
patient variable and endpoint follow-up information, after
patients were excluded due to loss of follow-up, missing data, and
considering only patients receiving EBRT alone.
Voxel-Based Tests Results
The tests identified voxel clusters (VCs) and individual
voxels within the pelvic anatomy where increased dose was
associated with the four genitourinary toxicity endpoints. Several
anatomical landmarks (different urethral regions, sphincters etc.)
are mentioned in the following descriptions. These structures
are not directly visible on the registration template CT images.
Their locations are assumed based on their anatomical proximity
to (or within) the prostate and the penile shaft, both visible
on the registration template CT images. I.e., it is assumed
the spongy urethra runs along the central axis of the visible
penile shaft (extending approximately 10.2 cm anteriorly from
the base of the penile shaft toward the surface of the patient on
the T1 template), the membranous urethra is located between
the apex of the prostate and the base of the penile shaft
(extending approximately 3.4 cm inferiorly from the prostatic
apex to the base of the penile shaft on the T1 template),
the bladder neck is located where the bladder and prostate
delineations meet (near the superior prostate boundary), and
the external and internal sphincters are located immediately
inferior to the prostatic apex and immediately superior to the
central superior boundary of the prostate. Figure 2 shows the
visibility of the penile shaft on the T1 registration template
CT image. It must be noted that these structures have not
been delineated and therefore references to their location
are approximate.
The following dose-toxicity patterns from all RADAR datasets
on T1 were generally reproduced on the other registration
templates (T2 and T3). The patterns were distorted according to
the anatomical difference between the templates, but otherwise
were similar, suggesting the revealed dose-toxicity association
patterns are largely independent of choice of registration
template (see Appendix Section 3 for these results).
Dysuria
The pelvic dose associations for dysuria are shown in Figure 3.
The consistent pattern is an association between a higher
incidence of dysuria and increased dose in the membranous
urethra and spongy urethra. This is particularly evident in the
uni-voxel HR maps, revealing VCs with HR > 1 (p < 0.05) in the
spongy urethra for RADAR, RT01 and Combined, and VCs with
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TABLE 2 | The number of patients in each trial dataset, broken down by endpoint and baseline variables, including follow-up information, for dysuria and haematuria.
RADAR RT01 CHHiP COMBINED
Dysuria
(grade ≥ 2)
Haematuria
(grade ≥ 1)
Dysuria
(grade ≥ 2)
Haematuria
(grade ≥ 1)
Dysuria
(grade ≥ 2)
Haematuria
(grade ≥ 1)
Dysuria
(grade ≥ 2)
Haematuria
(grade ≥ 1)
Total number of
patients
595 619 Total number of
patients
388 388 Total number of
patients
242 247 Total number of
patients
1225 1254
Events 79 (13.3%) 86 (13.9%) Events 36 (9.3%) 52 (13.4%) Events 11 (4.5%) 21 (8.5%) Events 126 (10.3%) 159 (12.7%)
Follow-up in months
(min, max, med, IQR)
(12, 84, 54,
30)
(5, 95, 53, 30) Follow-up in
months (min, max,
med, IQR)
(6, 158, 105,
57)
(6, 158, 102,
55)
Follow-up in
months (min, max,
med, IQR)
(6, 68, 60, 2) (6, 68, 60, 2) Follow-up in
months (min, max,
med, IQR)
(6, 158, 60,
30)
(5, 158, 61,
30)
Variables Definitions Definitions Definitions Definitions
Age1 Median 69.4 yrs 69.4 yrs Median 67.9 yrs 67.9 yrs Median 67.4 yrs 67.4 yrs Median 68.4 yrs 68.4 yrs
Prescribed
dose
[66Gy]
[70Gy]
[74Gy]
78
328
189
81
343
195
[64Gy]
[74Gy]
204
184
204
184
[57Gy]
[60Gy]
[74Gy]
82
82
78
87
83
77
[66Gy (RADAR),
64Gy (RT01),
57Gy and 60Gy
(CHHiP)]
[70Gy and 74Gy
(RADAR), 74Gy
(RT01),
74Gy (CHHiP)]
467
857
455
799
Disease risk [GS ≤ 7]
[GS > 7]
418
177
436
183
[T1b/c or T2a with
(PSA + (GS -
6)*10) < 15]
[T1b/c or T2a with
(PSA + (GS -
6)*10) ≥ 15
or T2b/T3a]
110
278
110
278
[T1b/c or T2a with
PSA ≤ 10 and GS
≤ 6]
[Any of the
following: Stage ≥
T2b, 10 < PSA ≤
20, GS > 6]
57
185
59
188
[Lower risk group
patients from each
respective dataset]
[Higher risk group
patients from each
respective dataset]
648
676
605
649
Cancer stage [T2]
[T3/T4]
427
168
448
171
[≤ T2a (T1b, T1c,
T2a)]
[> T2a (T2b, T3a)]
235
153
235
153
[≤ T2a (T1a, T1b,
T1c, T2a)]
[> T2a (T2b,
T2c, T3a)]
177
65
179
68
[Lower cancer
stage group
patients from each
respective dataset]
[Higher cancer
stage group
patients from each
respective dataset]
839
386
862
392
Baseline
PSAa
Median 14.04 ng/ml 14.00 ng/ml Median 13.80 ng/ml 13.80 ng/ml Median 11.70 ng/ml 11.70 ng/ml Median 13.60 ng/ml 13.50 ng/ml
Number of
beams
[3 beams]
[4 beams]
[5 beams]
[6 beams]
[≥ 7 beams]
65
311
79
84
56
65
331
81
87
55
[3 beams for
phase 1 of
treament]
[4 beams for
phase 1
of treament]
228
160
228
160
[≤ 4 beams]
[> 4 beams]
212
30
217
35
[≤ 4 beams
(RADAR), 3 beams
(RT01),
≤ 4 beams
(CHHiP)]
[> 4 beams
(RADAR), 4 beams
(RT01), > 4
beams (CHHiP)]
816
409
841
413
aThis variable was divided into two approximately equal subgroups split about the median value.
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TABLE 3 | The number of patients in each trial dataset, broken down by endpoint and baseline variables, including follow-up information, for incontinence and frequency.
RADAR RT01 CHHiP COMBINED
Incontinence
(grade ≥ 2)
Frequency
(grade ≥ 2)
Incontinence
(grade ≥ 2)
Frequency
(grade ≥ 2)
Incontinence
(grade ≥ 2)
Frequency
(grade ≥ 2)
Incontinence
(grade ≥ 2)
Frequency
(grade ≥ 2)
Total number of
patients
647 416 Total number of
patients
354 264 Total number of
patients
242 206 Total number of
patients
1243 886
Events 24 (3.7%) 125 (30.0%) Events 26 (7.3%) 131 (49.6%) Events 6 (2.5%) 33 (16.0%) Events 56 (4.5%) 289 (32.6%)
Follow-up in months
(min, max, med, IQR)
(12, 84, 54,
36)
(12, 84, 18,
36)
Follow-up in
months (min, max,
med, IQR)
(6, 152, 103,
48)
(12, 158, 60,
90)
Follow-up in
months (min, max,
med, IQR)
(6, 68, 60, 2) (6, 67, 60, 3) Follow-up in
months (min, max,
med, IQR)
(6, 158, 60,
30)
(6, 158, 48,
46)
Variables Definitions Definitions Definitions Definitions
Agea Median 69.5 yrs 69.1 yrs Median 67.6 yrs 68.6 yrs Median 67.3 yrs 67.3 yrs Median 68.4 yrs 68.4 yrs
Prescribed
dose
[66Gy]
[70Gy]
[74Gy]
82
358
207
43
230
143
[64Gy]
[74Gy]
186
168
141
123
[57Gy]
[60Gy]
[74Gy]
84
81
77
72
70
64
[66Gy (RADAR),
64Gy (RT01),
57Gy and 60Gy
(CHHiP)]
[70Gy and 74Gy
(RADAR), 74Gy
(RT01),
74Gy (CHHiP)]
433
810
326
560
Disease risk [GS ≤ 7]
[GS > 7]
457
190
288
128
[T1b/c or T2a with
(PSA + (GS -
6)*10) < 15]
[T1b/c or T2a with
(PSA + (GS -
6)*10) ≥ 15
or T2b/T3a]
101
253
74
190
[T1b/c or T2a with
PSA ≤ 10 and GS
≤ 6]
[Any of the
following: Stage ≥
T2b, 10 < PSA ≤
20, GS > 6]
58
184
51
155
[Lower risk group
patients from each
respective dataset]
[Higher risk group
patients from each
respective dataset]
616
627
413
473
Cancer stage [T2]
[T3/T4]
465
182
305
111
[≤ T2a (T1b, T1c,
T2a)]
[> T2a (T2b, T3a)]
216
138
156
108
[≤ T2a (T1a, T1b,
T1c, T2a)]
[> T2a (T2b,
T2c, T3a)]
176
66
152
53
[Lower cancer
stage group
patients from each
respective dataset]
[Higher cancer
stage group
patients from each
respective dataset]
857
386
613
273
Baseline
PSAa
Median 14.04 ng/ml 14.25 ng/ml Median 13.40 ng/ml 14.00 ng/ml Median 11.70 ng/ml 11.85 ng/ml Median 13.45 ng/ml 13.60 ng/ml
Number of
beams
[3 beams]
[4 beams]
[5 beams]
[6 beams]
[≥ 7 beams]
69
345
85
89
59
44
223
58
52
39
[3 beams for
phase 1 of
treament]
[4 beams for
phase 1
of treament]
212
142
159
105
[≤ 4 beams]
[> 4 beams]
212
30
181
25
[≤ 4 beams
(RADAR), 3 beams
(RT01),
≤ 4 beams
(CHHiP)]
[> 4 beams
(RADAR), 4 beams
(RT01), > 4
beams (CHHiP)]
838
405
607
279
aThis variable was divided into two approximately equal subgroups split about the median value.
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Marcello et al. Voxel-Based Dose-Toxicity Modeling
FIGURE 2 | (A) slices of the T1 registration template CT image with the penile shaft (containing the spongy urethra) visible despite not being delineated, outlined in
yellow dots. Mean dose difference maps between patients with and without (B) grade ≥ 2 dysuria and (C) grade ≥ 1 haematuria, on approximately the same urethral
slice as the image in (A) for comparison. It is evident that maximum dose difference is most likely occurring at the urethra.
HR> 1 (p> 0.05) here for CHHiP. These are most evident in the
axial and sagittal planes. For Combined, VCs with HR > 1 (p <
0.05) are also present in the vicinity of the membranous urethra.
For RT01, HR> 1 (p< 0.05) VCs are also found surrounding the
extraprostatic urethra, particularly laterally and in the posterior
beam region adjacent to the extraprostatic urethra (seen in the
axial plane). Although the permutation test found no significant
mean dose difference up to the p < 0.3 level, the corresponding
mean dose difference maps are generally consistent with these
associations. Patients who experienced dysuria had up to 7Gy
more planned dose on average in the corresponding associated
regions for RADAR, RT01 and Combined, and 4Gy for CHHiP.
Figure 7 shows that patients with and without dysuria in the
combined dataset had total doses of 48.2 and 42.2Gy, respectively
at a point near the membranous urethra, and 19.7 and 16.2Gy
at a point near the spongy urethra. It is also noteworthy that
patients experiencing dysuria had up to 7Gy more dose near
the bladder neck region for RADAR and RT01, with patients
in each cohort having mean total doses here of approximately
44 and 51Gy, respectively (see Appendix Section 4 for mean
dose distributions). For Combined, the dominant spongy and
membranous urethral dose-association is confirmed by the
corresponding multi-voxel results, as the LASSO selected voxels
with HR > 1 in the same regions as the HR > 1 (p <
0.05) VCs found in the uni-voxel map. The RADAR uni-voxel
maps on the T3 template (see Appendix Section 3) confirm the
membranous and spongy urethra correlation and reveal some
correlated voxels in the prostatic urethra also. In conclusion,
patients with increased dose in the vicinity of the membranous
and spongy urethra experienced a higher incidence of late grade
≥ 2 dysuria.
Haematuria
Figure 4 shows the results for haematuria. Similar to dysuria, the
major association is between increased dose in the membranous
and spongy urethra and increased haematuria. The uni-voxel HR
maps show VCs with HR > 1 (p < 0.05) in these regions for
RADAR (including for T3), CHHiP and Combined. RT01 results
are not consistent with these findings, revealing VCs with HR
> 1 (p < 0.05) in the posterior oblique beam regions. Reduced
dose in the lateral beam regions is also correlated with increased
haematuria, evident in the HR > 1 (p < 0.05) VCs found in
these regions for RADAR and Combined, particularly visible
on the coronal planes. Although the permutation test found no
regions of significant dose difference, the corresponding mean
dose difference maps confirm these dominant associations for all
datasets. For example, these reveal that patients who experienced
haematuria had up to 8, 5, and 6Gy more dose on average in
the vicinity of the membranous and spongy urethra for RADAR,
CHHiP and Combined respectively. Figure 7 shows that patients
with and without haematuria in the combined dataset had total
doses of 47.4 and 42.3Gy, respectively at a point near the
membranous urethra, and 18.6 and 16.5Gy at a point near the
spongy urethra. The dose difference maps also show that patients
with haematuria had up to 5, 8 and 4Gy more dose on average
near the bladder neck/trigone region for RT01, CHHiP and
Combined, respectively. The LASSO selected a voxel with HR
> 1 directly posterior to the spongy/membranous urethra region
for Combined. It also selected HR < 1 voxels in the lateral beam
region. In conclusion, patients with increased dose in the vicinity
of the spongy and membranous urethra experienced a higher
incidence of late grade ≥ 1 haematuria. Figure 2 shows how the
maximum dose difference for both dysuria and haematuria was
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FIGURE 3 | Results for dysuria. Corresponding axial, coronal and sagittal slices (top to bottom) of (A) mean dose difference maps, (B) uni-voxel Cox regression HR
and p-value maps and (C) multi-voxel Cox regression LASSO HR maps (with uni-voxel p-values for comparison), for respective data sets. “No Voxels Selected”
implies the LASSO selected no voxels of significant correlation with the endpoint within the patient region. The slices chosen for display are those which coincide with
the most dominant emergent dose-endpoint patterns, indicated in corresponding planes with dashed lines. Tones of red correspond to regions where increased dose
is associated with incidence of dysuria (HR > 1), while tones of blues correspond to regions where reduced dose is associated with incidence of dysuria (HR < 1). The
CTV is delineated in orange while the bladder and rectum are delineated in yellow. Anatomical directions left (L), right (R), superior (S), inferior (I), anterior (A), and
posterior (P) are also indicated.
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FIGURE 4 | Results for haematuria. Corresponding axial, coronal and sagittal slices (top to bottom) of (A) mean dose difference maps, (B) uni-voxel Cox regression
HR and p-value maps and (C) multi-voxel Cox regression LASSO HR maps (with uni-voxel p-values for comparison), for respective data sets. “No Voxels Selected”
implies the LASSO selected no voxels of significant correlation with the endpoint within the patient region. The slices chosen for display are those which coincide with
the most dominant emergent dose-endpoint patterns, indicated in corresponding planes with dashed lines. Tones of red correspond to regions where increased dose
is associated with incidence of haematuria (HR > 1), while tones of blues correspond to regions where reduced dose is associated with incidence of haematuria (HR
< 1). The CTV is delineated in orange while the bladder and rectum are delineated in yellow. Anatomical directions left (L), right (R), superior (S), inferior (I), anterior (A),
and posterior (P) are also indicated.
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located in the extraprostatic urethra (using the visibility of the
penile shaft).
Incontinence
Figure 5 shows the results for incontinence. There is some
evidence of an association between incontinence and increased
dose at the urethral sphincters, while the dominant association is
between incontinence and patients treated with posterior oblique
beams and posteriorly extended lateral beams. The uni-voxel
HR maps show VCs with HR > 1 (p < 0.05) in the vicinity
of the internal and external urethral sphincters for RADAR,
while a smaller HR > 1 (p < 0.05) VC is present near the
internal sphincter for Combined, most clearly visible in the
coronal plane. Larger VCs with HR > 1 (p < 0.05) are present
in the vicinity of the internal and external sphincters for RADAR
on the T3 template, with the LASSO confirming this internal
sphincter association by selecting HR> 1 voxels near the internal
sphincter. The permutation test found no VCs of dose difference
up to p < 0.3, but the corresponding dose difference maps did
show that patients with incontinence had up to 10Gy more
dose on average than patients without incontinence near both
sphincters for RADAR (more clearly seen on the T3 template),
and up to 5Gy more for Combined. RADAR patients had a mean
total dose of ∼69Gy near the internal sphincter and 65Gy at
the external sphincter, reading off the mean dose distribution
on the T3 template in Appendix Section 4. Larger VCs with
HR > 1 (p < 0.05) were present in the posterior oblique beam
regions for RADAR, RT01 and Combined, and in the posterior
extension of the lateral beams for Combined and RT01. The
dose difference maps show patients with incontinence had up to
10Gy more dose in the lateral beam posterior extension region
than patients without incontinence for RT01 and CHHiP, and
9Gy more for Combined. The LASSO selected HR > 1 voxels
in the posterior oblique beam lateral beam posterior lateral beam
extension regions for Combined. Only 6 grade ≥ 2 incontinence
events were present for CHHiP, thus all voxel HRs were at p >
0.05. In summary, patients with increased dose in the vicinity
of urethral sphincters and in posterior oblique beam and lateral
beam posterior extension regions had a higher incidence of late
grade ≥ 2 incontinence.
Frequency
Figure 6 shows the results for frequency. The uni-voxel HR
maps in this figure reveal the presence of VCs with HR > 1 (p
< 0.05) in anterior and posterior beam regions inferior to the
prostate for RADAR, the left lateral beam for RT01, and (like
RADAR) the posterior beam region extending inferiority to the
prostate for CHHiP and Combined. Combined showed VCs in
the posterior beam region extending inferiorly to the prostate.
The permutation test revealed VCs of significant dose difference
(p < 0.05) in this same region for Combined, where patients
with frequency experienced up to 6Gy more planned dose
on average than patients without frequency. RADAR patients
with frequency experienced up to 10Gy more average dose in
the same posterior beam region. The LASSO generally selected
voxels with HR > 1 in the same regions as the significant
HR > 1 VCs found in the uni-voxel maps, for RT01 and
Combined, further confirming these associations. In summary,
the dominant association revealed was the relationship between
patients experiencing more dose in regions extending inferiorly
and posteriorly to the prostate and a higher incidence of late
grade ≥ 2 frequency.
DISCUSSION
In this study, quality-assured and reviewed planning data
collected in multi-center clinical trials with extensive follow-up
was used to derive independent datasets for analysis. Deformable
registration of planned dose distributions onto common
templates enabled identification of associations between voxel-
dose andmeasures of GU toxicity across the pelvic anatomy. This
is the first study to generate dose-GU toxicity relationships of this
nature without the assumption that these necessarily occur on or
within OARs.
Although no individual voxel-based test in this study
addressed every typical shortcoming of voxel- based analyses,
each test did address specific problems such that a consistent
result across all techniques could be considered independent
of these issues. Late genitourinary toxicity differs from late
gastrointestinal (GI) toxicity in that the occurrence of late
GI toxicity generally reaches a plateau after 3 years post-
RT, while late GU toxicity more frequently extends past 3
years (33). This suggests extended follow-up is necessary for
the accurate estimation of late GU toxicity. The uni-voxel
and multi-voxel Cox regression tests utilized post-treatment
time-to-event endpoints with follow-up times extending
from approximately 6 to 13 years, enabling an accurate
accounting of late GU symptoms. The uni-voxel test controlled
for patient baseline characteristics, attempting to remove
their confounding influence upon discovered dose-toxicity
correlations. The LASSO regression ensured selected voxels,
which strongly correlated with GU endpoints, were independent
of correlation with other voxels. Incorporating all voxels in
the model together accounted for the multiple comparisons
problem. The permutation dose difference test similarly
accounted for the multiple comparisons problem, while also
being the only method of the three that excluded noisy
extraneous voxels.
Late grade ≥ 2 dysuria was consistently associated with
increased dose to the spongy and membranous urethra regions
in this study. Mylona et al. discovered a subregion in the
posterior bladder, partially in the trigone, where increased dose
was correlated with late grade ≥ 1 dysuria (8). Their study
was limited to the bladder and prostatic urethra. Utilizing
bladder dose-surface maps, Yahya et al. discovered a similar
correlation between late grade ≥ 2 dysuria and increased dose
at the posterosuperior bladder surface, near the bladder trigone,
however concluded that dysuria was not associated with dose
received directly by the trigone (10). The authors predicted,
rather, that dose in this region “might also correlate with dose
to other organs in the genitourinary system outside the bladder,”
alluding to further studies “anticipated to properly investigate
this possibility, including the dose to the posterior prostatic
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FIGURE 5 | Results for incontinence. Corresponding axial, coronal and sagittal slices (top to bottom) of (A) mean dose difference maps, (B) uni-voxel Cox regression
HR and p-value maps and (C) multi-voxel Cox regression LASSO HR maps (with uni-voxel p-values for comparison), for respective data sets. “No Voxels Selected”
implies the LASSO selected no voxels of significant correlation with the endpoint within the patient region. The slices chosen for display are those which coincide with
the most dominant emergent dose-endpoint patterns, indicated in corresponding planes with dashed lines. Tones of red correspond to regions where increased dose
is associated with incidence of incontinence (HR > 1), while tones of blues correspond to regions where reduced dose is associated with incidence of incontinence
(HR < 1). The CTV is delineated in orange while the bladder and rectum are delineated in yellow. Anatomical directions left (L), right (R), superior (S), inferior (I), anterior
(A), and posterior (P) are also indicated.
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FIGURE 6 | Results for frequency. Corresponding axial, coronal and sagittal slices (top to bottom) of (A) mean dose difference maps and regions of significant dose
difference determined by permutation test, (B) uni-voxel Cox regression HR and p-value maps and (C) multi-voxel Cox regression LASSO HR maps (with uni-voxel or
permutation test p-values for comparison), for respective data sets. The slices chosen for display are those which coincide with the most dominant emergent
dose-endpoint patterns, indicated in corresponding planes with dashed lines. Tones of red correspond to regions where increased dose is associated with incidence
of frequency (HR > 1), while tones of blues correspond to regions where reduced dose is associated with incidence of frequency (HR < 1). The CTV is delineated in
orange while the bladder and rectum are delineated in yellow. Anatomical directions left (L), right (R), superior (S), inferior (I), anterior (A), and posterior (P) are also
indicated.
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urethra and anterior urethra, which includes the membranous
and bulbous urethra.” This study has investigated the dose-
dysuria relationship in these regions and has indeed found
correlation primarily in the membranous and spongy/bulbous
urethra and not primarily in the prostatic urethra. The RADAR
T3 result did, however, expose some correlation in the prostatic
urethra. Thirteen patients in the RADAR cohort included in
the dysuria analysis in this study had reported strictures. It is
noteworthy that one stricture was found in the prostatic urethra
with the rest found in the membranous/spongy urethra. While
only 5 of the 13 patients with strictures presented with grade ≥2
dysuria, 8 of the 13 presented with grade ≥ 1 dysuria. Perhaps
the membranous/spongy urethra is particularly susceptible to the
radiation damage capable of inducing dysuria, such as stricture
formation. Dose escalation has been shown to increase urethral
strictures in the RADAR cohort (18).
However, upon examination of the standard deviation dose
distributions (see Appendix Section 4 or Figure 7 for just the
combined cohort), the maximum dose variation occurs in the
membranous/spongy urethra region with minimum variation
in the prostatic urethra region, for all trial datasets. This
is particularly evident in the T3 standard deviation dose
distribution. Therefore, this anterior urethral correlation may
have been exposed through sufficient intra-cohort dose-variance
in this region, while a potential prostatic urethral correlation
may be hidden due to lack of dose variation in the CTV.
Figure 7 contains mean dose distributions for the combined
cohort displaying dose values in the vicinity of the spongy and
membranous urethra, for patients with and without grade ≥ 2
dysuria. Patients with dysuria have a mean dose of 19.7 and
48.2Gy near the spongy and membranous urethra, respectively.
Therefore, this dose-toxicity relationship is occurring in the low
dose range at the spongy urethra and intermediate dose range at
the membranous urethra. It should be noted that doses <20Gy
are associated with this effect at the spongy urethra. One further
hypothesis is that the low dose bath at the distal spongy urethra
may reduce the capacity of stem cells to migrate back to the more
heavily irradiated prostatic (or even membranous) urethra where
they would facilitate urethral healing (34, 35). In conclusion,
there is strong evidence that radiation dose to the urethra is
associated with resulting dysuria. The membranous and spongy
urethra may be particularly susceptible, however dose to the
prostatic urethra is likely to be related to dysuria as well. Limiting
dose to the spongy urethra may be more realistic as the prostatic
urethra resides in the high dose region. Future studies delineating
the prostatic/membranous/spongy urethra and investigating the
dose-volume-dysuria relationship in these regions may further
characterize urethral dose sensitivity.
Late grade ≥ 1 haematuria was similarly associated with
increased dose to the spongy and membranous urethra regions.
Urinary bleeding has typically related to the high dose region
of the bladder (14, 36–38) where the bladder neck and trigone
reside, and has been observed in the bladder neck and trigone
at cystoscopy (8). Yahya et al. (10), however, in agreement
with the superior bladder subregion found by Mylona et al.
(8), determined that late haematuria was associated with dose
to the anterosuperior regions of the bladder, and concluded
that haematuria was not a result of dose to the trigone or
bladder neck, but rather to tissue damage in the bladder wall.
Although Inokuchi et al. investigated and found no dose-volume
association with haematuria at the prostatic urethra (14), no
study to date has investigated dose-haematuria association at
the membranous or spongy urethra. To the best of the author’s
knowledge this is the first study to have included these regions
of the urethra in localized dose-toxicity analysis. As a result,
an association with haematuria has been found in the extra-
prostatic urethra, contrary to the general pattern. This is not
beyond the scope of current evidence, however, as haematuria
can be caused by urinary tract infection and strictures (39).
As previously discussed, urethral strictures were present in
the cohort and can result from urethral radiation damage.
Considering patients in the subset of the RADAR cohort included
in the haematuria analysis, 9 out of the 12 patients with reported
spongy/membranous urethral strictures also had grade ≥ 1
haematuria. It is also plausible that radiation damage to the
anterior urethra can cause inflammation leading to urinary tract
infection. As demonstrated for dysuria, Figure 7 shows that this
haematuria effect is associated with doses lower than 20Gy
at the spongy urethra. Therefore, reduced stem cell migration
in response to the low dose bath at the spongy urethra may
also be contributing to this effect. Due to these considerations
and the similar association found with dysuria, limiting dose
to the anterior urethra may substantially reduce the incidence
of these two prominent urinary toxicities. Spongy urethral dose
could be reduced by taping down the penis to the thigh. Or
perhaps by using two anterior oblique beams instead of a single
anterior beam.
It should also be acknowledged that the above dysuria and
haematuria dose relationships were found in 3D-CRT patients
(from the RADAR and RT01 trials). In the current era, almost all
patients are treated with IMRT or VMAT which result in more
conformal dose distributions in comparison to 3D-CRT. It is
therefore very likely that the majority of contemporary patients
would receive less spongy urethral dose, perhaps eliminating the
need for the application of dose constraints or any dose reduction
scheme. This is even evident in the current study, with CHHiP
patients (treated with IMRT) experiencing less urethral dose
correlation and less events corresponding to both dysuria and
haematuria. It is also noteworthy that applying dose constraints
to the membranous urethra, which begins proximally at the
prostatic apex, may not be feasible due to its proximity to the
high dose PTV region. The reader is reminded that the primary
purpose of this study was not to discover dose constraints but
to explore the underlying causal relationships between localized
dose and toxicity without the assumption that these relationships
necessarily occurred at OAR sites (from which future analyses
may derive dose constraints if appropriate—see the third final
paragraph of this discussion).
Increased dose in the external and internal urethral sphincter
and in the posterior oblique beams was shown to correlate
with late grade ≥ 2 incontinence. It is established that urinary
incontinence can (40), andmost commonly does (41), result from
urethral sphincter malfunctioning. Although both the internal
and external sphincters are involved in maintaining continence,
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FIGURE 7 | (A) Mean dose distributions for patients with the given toxicity in the combined cohort, (B) mean dose distributions for patients without the given toxicity
in the combined cohort, and (C) standard deviation dose distributions maps for patients in the combined cohort dataset for the given toxicity. Each map displays the
dose value at a point in the vicinity of the distal spongy urethra (above) and membranous urethra (below). The top row represents the grade ≥2 dysuria dataset and
the bottom row the grade ≥1 haematuria dataset.
the internal sphincter is of primary importance (42). Mylona
et al. found a predictive subregion in the prostatic urethra for
incontinence, concluding this was related to damage to the
urethral sphincter (8). Yahya et al. found an association between
incontinence and dose to the posteroinferior bladder at the
trigone, suggesting this was likely related to dose received by the
internal sphincter (10). The sphincter muscles may be scarred
by irradiation, or dose to the nearby bladder neck may increase
ischemia and fibrosis and thus incontinence due to internal
sphincter damage (10). The association with the posterior oblique
beams may be a surrogate for dose directly to the sphincters,
although no direct evidence for this has been discovered. It is
recommended that clinicians be aware of the potential radiation
damage to the sphincters, while recognizing they do coincide
with the high dose region, and that a large scale clinical trial
did not reveal increasing incidence of incontinence with dose
escalation (43).
Late grade ≥ 2 frequency was associated with dose extending
inferiorly and posteriorly to the prostate and rectum. This may
indicate that patients treated with a posterior beam extending
inferiorly beyond the rectum had a higher incidence of frequency.
This result is largely unintuitive and difficult to rationalize. It is
noteworthy thatMylona et al. could not demonstrate a dosimetric
association with urinary frequency (8).
The relationships presented here are correlations that may
or may not represent anatomically-localized physiological dose-
toxicity associations. The low number of toxicity events, namely
<10% of the cohort for 7 of the 16 datasets, should reinforce
this suspicion. Only the uni-voxel Cox regression accounted for
intrinsic patient factors, and these represent only a sample of
possible patient cofactors that could confound the associations.
To ensure dose-toxicity relationships are independent of a
given patient factor, separating the cohort into this factor’s
subgroups prior to analysis is necessary. This, however, would
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reduce power, requiring a larger cohort to establish statically
meaningful associations. Furthermore, these relationships must
be interpreted in light of the differences in dosemaps from
the three trials. For example, the mean dose distributions
from respective trials (see Appendix Section 4) indicate that the
average CHHiP distribution is more conformal than that of
RADAR or RT01. This is consistent with the fact that CHHiP
patients received IMRT instead of 3D-CRT for RADAR and
RT01, and may explain why the number of toxicity events were
lower and correlation patterns were much weaker in CHHiP
datasets. It must also be noted that the follow-up times were not
identical between the datasets derived from the three trials. For
example, datasets from the RADAR trial included follow-up data
at 9 and 15 months post-treatment while the datasets from the
RT01 and CHHiP trails did. Defining the endpoints differently
in this way may bias the comparison and therefore it is that
data from the same timepoints are used in generating endpoints
when comparing applying analysis to different trials with the goal
of comparing results. Finally, it is recognized that the results
from the combined cohort (for all toxicity endpoints) are biased
toward the RADAR dataset as RADAR patients comprise a higher
proportion of this dataset than patients from the other two
trials. The goal of the combined analysis was to maximize the
statistical power available for each toxicity endpoint and observe
the resulting dose-toxicity patterns. The aforementioned bias was
therefore accepted as necessary to achieve this goal. Although, in
future analyses, if an adequate number of patients are available,
it is recommended that, in addition to combining all patients
together, an equal number of patients from each trial be included
in the combined dataset (or a form of normalization employed)
to remove bias from any individual trial dataset. Comparing
results from a combined cohort with those from a balanced
(or normalized cohort) would be useful in discerning the bias
introduced from the dominant dataset.
The permutation test is quite conservative. In the dose
difference comparison between patients with and without an
event pertaining to a given endpoint, it applies a global threshold
that cannot identify local maxima of dose difference. Also, due
to the large number of voxels compared, in order to adequately
account for the multiple statistical testing problem this threshold
can be quite high, and therefore may exclude not only local
regions of significant dose difference but also global regions.
Hence only large and statistically strong global dose differences
can be identified (and therefore p-value thresholds up to p <
0.3 were used). This could explain why, across all datasets and
endpoints, only in one dataset (Combined for frequency) was
a region of statistically significant dose difference discovered
by this test. A test more sensitive in identifying local maxima,
such as a threshold-free cluster enhancement test (44), may
be appropriate for further voxel-based analyses. Palorini et al.
(12) outline further reasons for being wary of a straightforward
application of the permutation test in the context of bladder
dose surface maps. These include (1) the distribution of t-scores
obtained in each pixel being significantly different from the null
distribution (invalidating the test’s assumption of a universal null
hypothesis), and (2) macro regions of heterogenous voxel dose
skewness reducing the probability of regions with less skewness of
registering a significant dose difference. Point (1) implies that the
test be overly restrictive, while (2) indicates the need for possibly
dividing the dose distribution into regions of relatively uniform
skewness and repeating the test on each region separately. This
may be an appropriate future directive for using this test in the
context of voxel-based analysis.
The assumption that planned dose is equivalent to delivered
dose, which differ in reality (45), is a major limitation of this
study. It has been shown that delivered dose can be a better
predictor of rectal toxicity than planned dose (46). As the
agreement between planned and delivered dose improves, or
delivered dose becomes more easily measurable, voxel-based
dose analyses will be more effective in identifying anatomically
localized dose-toxicity relationships. Cone beam CT daily
imaging, for example, could be used to measure cumulative
delivered dose across the course of treatment (47). Furthermore,
all voxel-based tests in this analysis were applied throughout the
entire pelvic region, including a broad range of late-responding
normal tissues. An alpha/beta value of 3 was chosen as it has
been regarded as generally representative of all late responding
normal tissues (48). It is acknowledged, however, that different
normal tissues respond differently with respect to different
toxicities, thus resulting in different alpha/beta values. Therefore,
an appropriate future direction would be to test the sensitivity of
results to different alpha/beta values, particularly with respect to
the different urinary toxicities. Another limitation could be the
registration accuracy and the suitability of the choice of exemplar
and anti-exemplar. The anatomical localization of the emergent
dose-toxicity patterns is directly dependent on registration
accuracy. A perfect registration would ensure the identified
patterns are in fact occurring at the presumed anatomical sites.
Diversity in the distribution of dose across each cohort is also
limiting, as the mean dose distributions are approximately 3 or 4
field treatments in all datasets (see Appendix Section 4 for mean
and standard deviation dose distributions). Greater diversity
in technique will enable more generalizable feature selection.
Differences in diversity between trials may also account for lack
of consistency in results across trials. For example, RADAR
treatments were allowed any combination of 3 or more beams,
while RT01 treatments were restricted to 3 or 4 beams in the
anterior/lateral/posterior directions. This has led to differences
in the spatial distribution of dose variation between trial cohorts,
resulting in different potential sites with sufficient variation for
exposing dose-toxicity associations.
Incorporating the voxel-based evidence into normal tissue
complication probability (NTCP) models may facilitate
translation of these results into clinical practice. Palma et al. have
derived a new NTCP philosophy to include voxel-based evidence
of OAR radio-sensitivity (49). Incorporating the evidence of
OAR sensitivity from this study into a model like this could
result in reduced toxicity for patients when applied to treatment
planning. It is also acknowledged that the majority of evidence
discovered in this study was from 3D-CRT patients. Therefore,
the methods here may need to be applied to a larger cohort of
patients treated with contemporary techniques before translation
is made to the clinic.
This study focused on urinary specific and not toxicities
related to sexual function. An exploration of the relationship
between erectile dysfunction (ED) and dose in a voxel-based
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manner is recommend for future analyses. Additionally, the
relationship between ED and dose to the penile bulb was studied
elsewhere for the RT01 and CHHiP patients (50, 51). Finally, the
study of the relationship between ED and dose is problematic in
cohorts that use additional ADT due to the impact of ADT on
various measures of sexual function including ED (52–54). The
RADAR trial, from which our primary dataset was derived, is
one such cohort. Additionally, it has previously been shown that
ADT did not increase urinary dysfunction (including dysuria,
haematuria, frequency and incontinence) in the RADAR cohort
(55). Similar studies have not been performed for the RT01 and
CHHiP cohorts, however, as trial arms did not vary in terms of
ADT duration. The impact of ADT may therefore be a confound
in the datasets derived from RT01 and CHHiP.
This was the first study performing a full voxel-based
analysis of dose-urinary toxicity relationships in the entire
pelvic anatomy, without the assumption that these occurred
exclusively at OAR sites. Associations between late dysuria and
haematuria and dose to the spongy and membranous urethra
have been newly identified, while dose to the urinary sphincters
and resulting incontinence has confirmed the idea that radiation
damage at the sphincter can cause incontinence.
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